$REGN
REGENERON PHARMACEUTICALS, INC.

2013 Q2 Form 10-Q Financial Statement

#000153217613000022 Filed on August 06, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $457.6M $304.4M
YoY Change 50.34% 182.35%
Cost Of Revenue $27.28M $21.84M
YoY Change 24.91% 5360.75%
Gross Profit $430.4M $282.6M
YoY Change 52.31% 163.09%
Gross Profit Margin 94.04% 92.82%
Selling, General & Admin $72.46M $47.71M
YoY Change 51.9% 93.92%
% of Gross Profit 16.84% 16.88%
Research & Development $187.5M $147.4M
YoY Change 27.2% 2.99%
% of Gross Profit 43.56% 52.16%
Depreciation & Amortization $9.700M $9.400M
YoY Change 3.19% 18.99%
% of Gross Profit 2.25% 3.33%
Operating Expenses $259.9M $195.1M
YoY Change 33.24% 16.33%
Operating Profit $158.1M $87.48M
YoY Change 80.73% -245.07%
Interest Expense $11.37M $11.24M
YoY Change 1.15% -380.9%
% of Operating Profit 7.19% 12.84%
Other Income/Expense, Net -$10.41M -$10.74M
YoY Change -3.02% -1173.5%
Pretax Income $147.7M $76.74M
YoY Change 92.45% -221.05%
Income Tax $60.32M
% Of Pretax Income 40.84%
Net Earnings $87.38M $76.74M
YoY Change 13.86% -222.78%
Net Earnings / Revenue 19.09% 25.21%
Basic Earnings Per Share $0.89 $0.81
Diluted Earnings Per Share $0.79 $0.70
COMMON SHARES
Basic Shares Outstanding 97.70M shares 94.59M shares
Diluted Shares Outstanding 111.1M shares 110.2M shares

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $538.0M $301.0M
YoY Change 78.74% -2.9%
Cash & Equivalents $381.7M $171.9M
Short-Term Investments $156.0M $129.0M
Other Short-Term Assets $98.00M $8.000M
YoY Change 1125.0% -57.89%
Inventory $57.16M $24.00M
Prepaid Expenses
Receivables $767.9M $435.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.561B $769.0M
YoY Change 103.04% 86.2%
LONG-TERM ASSETS
Property, Plant & Equipment $419.7M $372.0M
YoY Change 12.81% 2.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $173.0M $288.0M
YoY Change -39.93% 14.74%
Other Assets $15.21M $28.00M
YoY Change -45.68% 40.0%
Total Long-Term Assets $816.9M $689.0M
YoY Change 18.56% 8.68%
TOTAL ASSETS
Total Short-Term Assets $1.561B $769.0M
Total Long-Term Assets $816.9M $689.0M
Total Assets $2.378B $1.458B
YoY Change 63.12% 39.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $24.00M $26.00M
YoY Change -7.69% -3.7%
Accrued Expenses $129.0M $101.0M
YoY Change 27.72% 83.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $203.8M $183.0M
YoY Change 11.37% 34.56%
LONG-TERM LIABILITIES
Long-Term Debt $473.0M $445.0M
YoY Change 6.29% 179.87%
Other Long-Term Liabilities $10.20M $235.0M
YoY Change -95.66% -14.23%
Total Long-Term Liabilities $10.20M $680.0M
YoY Change -98.5% 57.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $203.8M $183.0M
Total Long-Term Liabilities $10.20M $680.0M
Total Liabilities $884.9M $863.0M
YoY Change 2.54% 51.67%
SHAREHOLDERS EQUITY
Retained Earnings -$330.8M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.493B $594.7M
YoY Change
Total Liabilities & Shareholders Equity $2.378B $1.458B
YoY Change 63.12% 39.26%

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income $87.38M $76.74M
YoY Change 13.86% -222.78%
Depreciation, Depletion And Amortization $9.700M $9.400M
YoY Change 3.19% 18.99%
Cash From Operating Activities $128.2M -$78.40M
YoY Change -263.52% 130.59%
INVESTING ACTIVITIES
Capital Expenditures -$34.50M -$12.80M
YoY Change 169.53% -13.51%
Acquisitions
YoY Change
Other Investing Activities $151.1M -$126.3M
YoY Change -219.64% -180.04%
Cash From Investing Activities $116.6M -$139.2M
YoY Change -183.76% -197.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -43.50M -5.000M
YoY Change 770.0% -149.5%
NET CHANGE
Cash From Operating Activities 128.2M -78.40M
Cash From Investing Activities 116.6M -139.2M
Cash From Financing Activities -43.50M -5.000M
Net Change In Cash 201.3M -222.6M
YoY Change -190.43% -286.9%
FREE CASH FLOW
Cash From Operating Activities $128.2M -$78.40M
Capital Expenditures -$34.50M -$12.80M
Free Cash Flow $162.7M -$65.60M
YoY Change -348.02% 241.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.69
CY2013Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
153826000 USD
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
111345000 USD
CY2013Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
24418000 USD
CY2012Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
38934000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
593207000 USD
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
767865000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1166000 USD
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3429000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1763508000 USD
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1827471000 USD
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
7876000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
61444000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
73137000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
98728000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42850000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-253812000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
28162000 USD
CY2013Q2 us-gaap Assets
Assets
2378259000 USD
CY2012Q4 us-gaap Assets
Assets
2080490000 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
1561362000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
1206012000 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
354990000 USD
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
66835000 USD
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
63442000 USD
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
3393000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
351565000 USD
CY2013Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
326859000 USD
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
354958000 USD
CY2013Q2 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
500000 USD
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
500000 USD
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
702000 USD
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
651000 USD
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2
702000 USD
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2
51000 USD
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
670000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
381675000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230276000 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
171943000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
483610000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
151399000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-311667000 USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
75709000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
87885000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
183987000 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
85591000 USD
CY2013Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
4700000 USD
CY2013Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
308116000 USD
CY2012Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
296518000 USD
CY2013Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
27283000 USD
CY2012Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
21843000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
34141000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
55304000 USD
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
299539000 USD
us-gaap Costs And Expenses
CostsAndExpenses
586153000 USD
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
216921000 USD
us-gaap Costs And Expenses
CostsAndExpenses
426509000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
92522000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33809000 USD
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
34266000 USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
131822000 USD
CY2013Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
119672000 USD
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
148134000 USD
CY2013Q2 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
38927000 USD
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
192022000 USD
CY2013Q2 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
208707000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19109000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17833000 USD
CY2012Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
99913000 USD
CY2013Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
108151000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.91
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.89
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.94
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.81
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.70
CY2013Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.408
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.357
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.060
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
39760000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19987000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
7876000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
147692000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
88394000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
289523000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
76743000 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60316000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
103273000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
35592000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
32789000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
182896000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
332345000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11579000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-17669000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
51697000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19517000 USD
us-gaap Increase Decrease In Restricted Cash And Investments
IncreaseDecreaseInRestrictedCashAndInvestments
USD
us-gaap Increase Decrease In Restricted Cash And Investments
IncreaseDecreaseInRestrictedCashAndInvestments
469000 USD
CY2012Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
831000 shares
CY2013Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2645000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
341000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2337000 shares
CY2012Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14055000 shares
CY2013Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10291000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10296000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
13964000 shares
us-gaap Interest Expense
InterestExpense
23040000 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
11365000 USD
us-gaap Interest Expense
InterestExpense
22396000 USD
CY2012Q2 us-gaap Interest Expense
InterestExpense
11236000 USD
CY2012Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2570000 USD
CY2013Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10429000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
28638000 USD
CY2013Q2 us-gaap Inventory Net
InventoryNet
57159000 USD
CY2013Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5380000 USD
CY2012Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4862000 USD
CY2012Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3600000 USD
CY2013Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
6200000 USD
CY2013Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
34580000 USD
CY2012Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
14656000 USD
us-gaap Inventory Write Down
InventoryWriteDown
4900000 USD
us-gaap Inventory Write Down
InventoryWriteDown
8400000 USD
CY2013Q2 us-gaap Inventory Write Down
InventoryWriteDown
1700000 USD
CY2012Q2 us-gaap Inventory Write Down
InventoryWriteDown
6500000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1111000 USD
CY2013Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
954000 USD
CY2012Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
501000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1410000 USD
CY2013Q2 us-gaap Liabilities
Liabilities
884922000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
835105000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2080490000 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2378259000 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
203802000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
163550000 USD
us-gaap Licenses Revenue
LicensesRevenue
11786000 USD
us-gaap Licenses Revenue
LicensesRevenue
11786000 USD
CY2013Q2 us-gaap Licenses Revenue
LicensesRevenue
5893000 USD
CY2012Q2 us-gaap Licenses Revenue
LicensesRevenue
5893000 USD
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
77819000 USD
CY2013Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
155831000 USD
CY2013Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
173328000 USD
CY2012Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
271230000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-22827000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-31958000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31055000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-123422000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
214412000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-165418000 USD
us-gaap Net Income Loss
NetIncomeLoss
88394000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
87376000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
76743000 USD
us-gaap Net Income Loss
NetIncomeLoss
186250000 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10411000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21630000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21285000 USD
CY2012Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10735000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
311153000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
158103000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
87478000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
109679000 USD
CY2013Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
19945000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
19569000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23100000 USD
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15211000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-509000 USD
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1785000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2263000 USD
CY2012Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1034000 USD
CY2012Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
6550000 USD
CY2013Q2 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
6770000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7259000 USD
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10200000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-11056000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-18323000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
73137000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
61444000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
282643000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
270907000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
23927000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
55656000 USD
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
56663000 USD
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
108913000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
39631000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34300000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
171881000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
307244000 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
419651000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
379940000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
997000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1014000 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
187463000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
286235000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
367762000 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
147373000 USD
CY2012Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
8186000 USD
CY2013Q2 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
USD
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-330804000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-517054000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
184802000 USD
CY2012Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
88988000 USD
CY2013Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
85529000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
173993000 USD
CY2013Q1 us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs (including Medicaid), distribution-related fees, prompt pay discounts, product returns, and other sales-related deductions. </font></div></div>
us-gaap Revenues
Revenues
536188000 USD
us-gaap Revenues
Revenues
897306000 USD
CY2012Q2 us-gaap Revenues
Revenues
304399000 USD
CY2013Q2 us-gaap Revenues
Revenues
457642000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
2074000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
1352000 USD
CY2013Q2 us-gaap Royalty Revenue
RoyaltyRevenue
1223000 USD
CY2012Q2 us-gaap Royalty Revenue
RoyaltyRevenue
875000 USD
CY2012Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
199519000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
652633000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
327450000 USD
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
333893000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
106133000 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72463000 USD
CY2012Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47705000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149723000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
42850000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
97473000 USD
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
shares
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
USD
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30498000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
39634000 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
1493337000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
1245385000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
485732000 USD
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
594657000 USD
CY2013Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
23037000 USD
CY2012Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
18826000 USD
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
41041000 USD
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
36830000 USD
CY2013Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13360000 shares
CY2012Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15578000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
14981000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13016000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108998000 shares
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110167000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110305000 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97700000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97289000 shares
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111060000 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94589000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94017000 shares
CY2012Q2 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
5900000 USD
CY2012Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
8600000 USD
CY2013Q2 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
8100000 USD
CY2011Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
6200000 USD
CY2012Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
10985000 USD
CY2013Q2 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
20295000 USD
CY2013Q2 regn Accrued Sales Related Deductions And Royalties
AccruedSalesRelatedDeductionsAndRoyalties
49408000 USD
CY2012Q4 regn Accrued Sales Related Deductions And Royalties
AccruedSalesRelatedDeductionsAndRoyalties
21870000 USD
regn Cost Of Collaboration Manufacturing
CostOfCollaborationManufacturing
13364000 USD
CY2012Q2 regn Cost Of Collaboration Manufacturing
CostOfCollaborationManufacturing
USD
regn Cost Of Collaboration Manufacturing
CostOfCollaborationManufacturing
USD
CY2013Q2 regn Cost Of Collaboration Manufacturing
CostOfCollaborationManufacturing
12330000 USD
CY2013Q2 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
14916000 USD
CY2012Q4 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
17022000 USD
CY2013Q2 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
78740000 USD
CY2012Q4 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
76520000 USD
CY2013Q2 regn Facility Lease Obligation Including Reimbursements
FacilityLeaseObligationIncludingReimbursements
4700000 USD
CY2012Q4 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
1374000 USD
CY2013Q2 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
794000 USD
CY2013Q2 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
164392000 USD
CY2012Q4 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
159436000 USD
CY2012Q2 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
692000 shares
CY2013Q2 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
424000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
383000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
676000 shares
regn Non Cash Interest Expense
NonCashInterestExpense
11315000 USD
regn Non Cash Interest Expense
NonCashInterestExpense
11191000 USD
regn Numberoffamiliesofnovelantibodies
Numberoffamiliesofnovelantibodies
2
CY2013Q2 regn Numberoffamiliesofnovelantibodies
Numberoffamiliesofnovelantibodies
2
CY2012Q2 regn Other Collaboration Revenue
OtherCollaborationRevenue
9124000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
21607000 USD
CY2013Q2 regn Other Collaboration Revenue
OtherCollaborationRevenue
31104000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
46011000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000872589
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS INC

Files In Submission

Name View Source Status
0001532176-13-000022-index-headers.html Edgar Link pending
0001532176-13-000022-index.html Edgar Link pending
0001532176-13-000022.txt Edgar Link pending
0001532176-13-000022-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
regn-20130630.xml Edgar Link completed
regn-20130630.xsd Edgar Link pending
regn-20130630_cal.xml Edgar Link unprocessable
regn-20130630_def.xml Edgar Link unprocessable
regn-20130630_lab.xml Edgar Link unprocessable
regn-20130630_pre.xml Edgar Link unprocessable
regn-63013x10q.htm Edgar Link pending
regn-ex_101x6302013x10q.htm Edgar Link pending
regn-ex_102x6302013x10q.htm Edgar Link pending
regn-ex_103x6302013x10q.htm Edgar Link pending
regn-ex_104x6302013x10q.htm Edgar Link pending
regn-ex_105x6302013x10q.htm Edgar Link pending
regn-ex_106x6302013x10q.htm Edgar Link pending
regn-ex_107x6302013x10q.htm Edgar Link pending
regn-ex_108x6302013x10q.htm Edgar Link pending
regn-ex_109x6302013x10q.htm Edgar Link pending
regn-ex_311x6302013x10q.htm Edgar Link pending
regn-ex_312x6302013x10q.htm Edgar Link pending
regn-ex_32x6302013x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending